logo BDSP

Base documentaire


  1. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer.

    Article - En anglais

    Purpose 

    A phase III trial by the Gynecologic Oncology Group (GOG) provides strong evidence that a new alternative therapy-paclitaxel (Taxol ; Bristol-Myers Squibb Co, Princeton, NJ) in combination with cisplatin (Platinol ; Bristol-Myers Squibb Co) - is clinically more effective than the standard therapy using cyclophosphamide (Cytoxan ; Bristol-Myers Squibb Co) in combination with cisplatin in the treatment of advanced ovarian cancer.

    We conducted a pharmacoeconomic analysis to determine whether the alternative paclitaxel-cisplatin (TP) therapy is cost-effective (CE) in comparison to standard cyclophosphamide-cisplatin (CP) therapy.

    Methods 

    Using an economic model, we applied cost data figures to resource utilization data derived from the two arms of the GOG trial.

    We examined paclitaxel benefits in terms of increased mean survival time, as well as median survival time.

    Estimates of the cumulative proportion surviving in the trial were based on Kaplan-Meier procedures.

    Results 

    Per year of life gained (YLG), TP therapy costs more ($19,820 more for inpatient treatment ; $21,222 outpatient) than CP treatment.

    Conclusion 

    The TP regimen's increased mean survival cost per YLG (inpatient and outpatient settings) adds a substantial benefit at an acceptable cost compared with CP therapy.

    Mots-clés Pascal : Carcinome, Ovaire, Paclitaxel, Chimiothérapie, Traitement, Cyclophosphamide, Cisplatine, Analyse coût efficacité, Aspect économique, Etude comparative, Etats Unis, Amérique du Nord, Amérique, Homme, Femelle, Stade avancé, Anticancéreux, Tumeur maligne, Appareil génital femelle pathologie, Ovaire pathologie, Taxane dérivé, Moutarde à l'azote, Oxazaphosphinane dérivé, Platine II Complexe, Economie santé

    Mots-clés Pascal anglais : Carcinoma, Ovary, Paclitaxel, Chemotherapy, Treatment, Cyclophosphamide, Cisplatin, Cost efficiency analysis, Economic aspect, Comparative study, United States, North America, America, Human, Female, Advanced stage, Antineoplastic agent, Malignant tumor, Female genital diseases, Ovarian diseases, Taxane derivatives, Nitrogen mustard, Oxazaphosphinane derivatives, Platinum II Complexes, Health economy

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0186172

    Code Inist : 002B02R02. Création : 21/05/1997.